Multiple Sclerosis

Drug Approval Name: Briumvi Active Ingredient: ublituximab-xiiy Indications: To treat relapsing forms of multiple sclerosis Approval Date: 12/28/2022 Company: TG Therapeutics, Inc. Learn more:  https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761238s000lbl.pdf